Companies Scheduled to Present at the Annual J.P. Morgan Healthcare Conference - Research Report on Mettler-Toledo, BioMarin,

Companies Scheduled to Present at the Annual J.P. Morgan Healthcare Conference
  - Research Report on Mettler-Toledo, BioMarin, DexCom, Spectranetics, and
                                    Acorda

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, January 10, 2014

NEW YORK, January 10, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting
Mettler-Toledo International Inc. (NYSE: MTD), BioMarin Pharmaceutical Inc.
(NASDAQ: BMRN), DexCom, Inc. (NASDAQ: DXCM), The Spectranetics Corporation
(NASDAQ: SPNC), and Acorda Therapeutics, Inc. (NASDAQ: ACOR). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Mettler-Toledo International Inc. Research Report

On January 7, 2014, Mettler-Toledo International Inc. (Mettler-Toledo)
announced that it will participate at the Annual J.P. Morgan Healthcare
Conference in San Francisco, California on January 14, 2014 at 3:30 p.m. PT /
6:30 p.m. ET. The Company informed that a live webcast of the presentation
will be available on the Investor Relations page of Mettler-Toledo's website.
The Full Research Report on Mettler-Toledo International Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at: 

http://www.analystscorner.com/r/full_research_report/ac69_MTD

--

BioMarin Pharmaceutical Inc. Research Report

On January 7, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced that its
CEO, Jean-Jacques Bienaime is scheduled to present a company update at the
32^nd Annual J.P. Morgan Healthcare Conference on January 13, 2014 at 10:30
a.m. PT. According to the Company, interested parties may access a live audio
webcast of the conference call via the Investors section of the BioMarin's
website. The Full Research Report on BioMarin Pharmaceutical Inc. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/9b6c_BMRN

--

DexCom, Inc. Research Report 

On January 7, 2014, DexCom, Inc. (DexCom) announced that it will participate
at the J.P. Morgan 2014 Healthcare Conference at the Westin St. Francis Hotel
in San Francisco. According to the Company, CEO of DexCom, Terry Gregg is
scheduled to make the presentation on January 14, 2014 at 3:30 p.m. PST. The
Full Research Report on DexCom, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

http://www.analystscorner.com/r/full_research_report/d377_DXCM

--

The Spectranetics Corporation Research Report

On January 6, 2014, The Spectranetics Corporation (Spectranetics) announced
that its management team will represent the Company at the J.P. Morgan 32^nd
Annual Healthcare Conference on January 15, 2014 in San Francisco. According
to the Company, Spectranetics' management is scheduled to present on the
aforesaid date at 5:30 p.m. ET. Spectranetics informed that interested parties
can access the live audio webcast of the presentation at the Company's
website. The Full Research Report on The Spectranetics Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/82e6_SPNC

--

Acorda Therapeutics, Inc. Research Report

On January 7, 2014, Acorda Therapeutics, Inc. (Acorda) announced its
participation at upcoming the J.P. Morgan Healthcare Conference, to be held at
the Westin St. Francis Hotel in San Francisco, California. According to the
Company, Ron Cohen, M.D., President and CEO of Acorda, is scheduled to present
on January 13, 2014 at 11:00 a.m. PT. According to the Acorda, a live audio
webcast of the presentation can be accessed under "Investor Events" in the
Investor section of the Company's website. The Full Research Report on Acorda
Therapeutics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/d67c_ACOR

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.